Table 2.
Unadjusted and adjusted Cox proportional hazards models for major adverse cardiac events according to risk groups and its individual components.
| Variables | No adjustment HR (95% CI) | P Value | Model 1&HR (95% CI) | P Value | Model 2¶ HR (95% CI) | P Value | Model 3ϕ HR (95% CI) | P Value | Model 4§ HR (95% CI) | P Value | Model 5£ HR (95%CI) | P Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk group analysis* | ||||||||||||
| Low-risk | 1.00 (Reference) | 1.00 (Reference) |
1.00 (Reference) | 1.00 (Reference) |
1.00 (Reference) |
1.00 (Reference) |
||||||
| Intermediate-risk | 3.08 (2.10–4.53) |
<0.001 | 3.00 (2.04–4.40) |
<0.001 | 2.67 (1.53–3.36) |
<0.001 | 2.77 (1.85–4.15) |
<0.001 | 2.18 (1.48–3.20) |
<0.001 | 2.65 (1.76–3.98) |
<0.001 |
| High-risk | 11.63 (7.85–17.23) |
<0.001 | 10.96 (7.38–16.26) |
<0.001 | 6.26 (4.12–9.53) |
<0.001 | 10.21 (6.32–16.51) |
<0.001 | 6.90 (4.60–10.34) |
<0.001 | 8.15 (5.01–13.24) |
<0.001 |
| Risk stratification from low to high | 3.50 (2.90–4.23) |
<0.001 | 3.40 (2.81–4.11) |
<0.001 | 2.56 (2.09–3.15) |
<0.001 | 3.27 (2.57–4.17) |
<0.001 | 2.76 (2.26–3.37) |
<0.001 | 2.89 (2.27–3.68) |
<0.001 |
| Categorical biomarker analysis | ||||||||||||
| WBC ≥8.62 × 109/L | 3.35 (2.53–4.43) |
<0.001 | 3.36 (2.54–4.44) |
<0.001 | 2.17 (1.61–2.92) |
<0.001 | 3.33 (2.35–4.74) |
<0.001 | 2.17 (1.63–2.89) |
<0.001 | 2.85 (2.00–4.06) |
<0.001 |
| Hemoglobin <128 g/L | 2.94 (2.20–3.94) |
<0.001 | 2.62 (1.92–3.59) |
<0.001 | 1.77 (1.27–2.48) |
0.001 | 1.69 (1.10–2.59) |
0.016 | 2.23 (1.65–3.00) |
<0.001 | 1.58 (1.02–2.46) |
0.042 |
| MPV ≥12.9 fL | 2.41 (1.85–3.16) |
<0.001 | 2.45 (1.87–3.20) |
<0.001 | 2.43 (1.85–3.21) |
<0.001 | 3.56 (2.31–5.49) |
<0.001 | 2.53 (1.94–3.31) |
<0.001 | 2.92 (1.88–4.53) |
<0.001 |
| Continuous biomarkers analysis | ||||||||||||
| WBC, per 1 × 109/L increment | 1.13 (1.11–1.17) |
<0.001 | 1.14 (1.11–1.17) |
<0.001 | 1.05 (1.01–1.08) |
0.011 | 1.80 (1.54–2.11) |
<0.001 | 1.06 (1.03–1.09) |
<0.001 | 1.45 (1.28–1.65) |
<0.001 |
| Hemoglobin, per g/L increment | 0.98 (0.97–0.98) |
<0.001 | 0.98 (0.97–0.99) |
<0.001 | 0.99 (0.98–1.00) |
0.002 | 0.97 (0.96–0.99) |
0.001 | 0.98 (0.98–0.99) |
<0.001 | 0.98 (0.96–1.00) |
0.020 |
| MPV, per fL increment | 1.29 (1.18–1.41) |
<0.001 | 1.30 (1.19–1.42) |
<0.001 | 1.30 (1.19–1.42) |
<0.001 | 1.83 (1.50–2.22) |
<0.001 | 1.30 (1.19–1.42) |
<0.001 | 1.73 (1.41–2.11) |
<0.001 |
*See Table 1 footnotes for definitions of risk categories determined by white blood cell (WBC) count, hemoglobin, and mean platelet volume (MPV) levels.
&Adjusted for demographic variables (age, gender, and body mass index).
¶Adjusted for demographic and clinical covariates (age, gender, body mass index, smoker, diagnosis of hypertension, diabetes, dyslipidemia, history of myocardial infarction, percutaneous coronary intervention, stroke, heart rate, systolic blood pressure, Killip class, cardiac arrest on admission, elevated cardiac enzymes, ST-segment deviation on electrocardiograms, baseline creatinine, glucose, low-density lipoprotein levels, and left ventricle ejection fraction).
ϕAdjusted for other CBC components (neutrophil, lymphocyte, eosinophil, basophil, monocyte, red blood cell count, hematocrit, mean corpuscular volume, red blood cell distribution width, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, platelet distribution width, platelet large cell ratio, and plateletcrit).
§Adjusted for the Global Registry of Acute Coronary Events (GRACE) score.
£Adjusted for variables that were statistically different among the 3 study groups and established risk factors for adverse outcomes following acute coronary syndrome (age, gender, diabetes, heart rate, systolic blood pressure, Killip class, cardiac arrest on admission, baseline neutrophil, eosinophil, basophil, monocyte, red blood cell count, hematocrit, mean corpuscular volume, red blood cell distribution width, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, platelet distribution width, platelet large cell ratio, plateletcrit, creatinine, glucose, and low-density lipoprotein levels, elevated cardiac enzymes, ST-segment deviation on electrocardiograms, left ventricle ejection fraction, GRACE score, and acute coronary syndrome presentation).